June 3, 2022 11:53 AM EDTUpdated 05:39 PM

#ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival

Nicole DeFeudis

Editor

Johnson & Johnson and AbbVie popped the cork on some preliminary data showing Imbruvica, the original BTK inhibitor, kept a rare and aggressive form of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug

#AS­CO22: Im­bru­vi­ca keeps ag­gres­sive blood can­cer at bay for 6+ years, but miss­es the mark in over­all sur­vival

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

#ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Regeneron forges ahead in factor XI despite field’s mixed results

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug